Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2014 event was held May 30-June 3. The next ASCO Annual Meeting will be held May 29-June 2, 2015, in Chicago. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
A new program at The University of Texas M.D. Anderson Cancer Center showed that specifically matching targeted therapy to genetic changes in the tumors of patients with advanced cancer, an approach called personalized medicine, better controlled tumor growth and increased survival. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Not all cancers have the same targets, and targeted therapy is often chosen based on the genes, proteins, and other factors involved in a person's cancer.
A large study on combining human papillomavirus (HPV) and Pap testing for regular cervical cancer screening showed that it is safe for women to have cervical cancer screening every three years instead of every year. The study also showed that HPV testing identified more women at high risk for cervical cancer than Pap testing. HPV, a virus most commonly passed from person to person during sexual activity, is a major risk factor for cervical cancer.
A large study of more than 12,000 Swedish men showed that first-time prostate-specific antigen (PSA) levels for men age 44 to 50 predicts the chance of developing metastatic prostate cancer (cancer that has spread to other parts of the body) or dying of the disease up to 30 years later. PSA is found in higher-than-normal levels in men with various conditions of the prostate, including prostate cancer and noncancerous conditions.
An evaluation of the lifestyle habits of more than 13,000 healthy women with a high risk of breast cancer showed that the risk of breast, lung, and colon cancers is higher for women who have smoked for a long time, compared with women who did not smoke or who smoked for a shorter time.
In a recent study, researchers found that maintenance therapy with olaparib, a type of drug called a PARP inhibitor, increased the amount of time it took for recurrent ovarian cancer (cancer that has come back after treatment) to worsen. Maintenance therapy is ongoing treatment that is given after the standard treatment to help control the growth of cancer.
In a recent study, the drug cabozantinib helped manage various advanced cancers, particularly prostate, ovarian, and liver cancers. The drug also helped shrink bone metastases (cancer that has spread to the bone). Cabozantinib is a type of targeted therapy, which means it targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A large study evaluating ovarian cancer screening showed that using both a CA-125 blood test and transvaginal ultrasound to find early ovarian cancer did not reduce the risk of dying from the disease and resulted in unnecessary follow-up procedures. The CA-125 blood test measures the amount of a tumor marker called CA-125, which may be found in higher levels in women with ovarian cancer. A transvaginal ultrasound uses sound waves to create pictures of the ovaries. Both tests are used to evaluate the symptoms of ovarian cancer, its stage, and the effectiveness of treatment.
In an analysis of the genes of more than 2,200 patients, researchers found that patients with specific genetic variations were more likely to develop peripheral neuropathy from chemotherapy with drugs called taxanes than patients without these changes. Peripheral neuropathy is nerve damage that causes pain and numbness. About one-third of patients who receive chemotherapy with a taxane develop neuropathy, and it can keep a patient from receiving a full dose of chemotherapy. The only other known risks of peripheral neuropathy are older age and a history of diabetes.